Target intelligence / Profile preview

Hepatocellular transport system

Molecular classification
Transporter, Solute carrier, ATP-binding cassette transporter
01

Overview

The hepatocellular transport system is a complex network of membrane-bound proteins located on the basolateral (sinusoidal) and apical (canalicular) membranes of hepatocytes. These transporters, primarily belonging to the Solute Carrier (SLC) and ATP-Binding Cassette (ABC) superfamilies, facilitate the bidirectional movement of endogenous substances—such as bile acids, bilirubin, and hormones—and exogenous compounds like drugs and toxins. Sinusoidal transporters like OATP1B1 and NTCP mediate the uptake of compounds from the blood, while canalicular transporters like BSEP and MDR1 drive the excretion of metabolites into the bile. This system is a fundamental determinant of hepatic clearance and systemic drug exposure, making it a focal point for pharmacokinetics and toxicology. Genetic polymorphisms or pharmacological inhibition of these transporters can lead to impaired bile flow (cholestasis), hyperbilirubinemia, and severe drug-drug interactions. Consequently, evaluating the interaction of new chemical entities with the hepatocellular transport system is a regulatory requirement in drug development to mitigate the risk of hepatotoxicity and adverse clinical outcomes.

Other names
Hepatic transport systemHepatocyte transportersLiver transport systemSinusoidal and canalicular transport system
02

Mechanism of action

Inhibition of hepatic uptake transporters (e.g., OATP1B1/1B3), inhibition of bile salt export pump (BSEP), or acting as competitive substrates for hepatic clearance.

03

Biological functions

Bile acid transportXenobiotic metabolismBilirubin transportDrug uptakeDrug effluxLipid homeostasis
04

Disease associations

CholestasisDrug-induced liver injury (DILI)HyperbilirubinemiaJaundiceDubin-Johnson syndromeRotor syndromeProgressive familial intrahepatic cholestasis (PFIC)
05

Safety considerations

Drug-induced liver injury (DILI)Cholestatic liver diseaseClinically significant drug-drug interactions (DDIs)Increased systemic exposure of co-administered drugs
06

Interacting drugs

Atorvastatin

8 more in the full profile.

07

Biomarkers

Total bilirubinConjugated bilirubinSerum bile acidsCoproporphyrin ICoproporphyrin III

Beyond the preview

Go deeper on Hepatocellular transport system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatocellular transport system.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call